MIT's Noninvasive Therapy Shows Promise Against Chemo Brain

Using light and sound at 40 hertz, the treatment developed for Alzheimer's also mitigates chemotherapy's cognitive effects, with human trials underway.

• MIT researchers have developed a noninvasive treatment using light and sound at 40 hertz to mitigate the cognitive effects of chemotherapy, known as 'chemo brain'.
• The treatment, initially aimed at Alzheimer's disease, has shown to protect brain cells, reduce inflammation, and improve memory and executive function in mice.
• Phase 1 clinical trials in humans with early-stage Alzheimer's have found the treatment to be safe, offering neurological and behavioral benefits.
• The therapy's effectiveness extends to various chemotherapy drugs and holds promise for treating other neurological disorders, including Parkinson's disease and multiple sclerosis.
• Cognito Therapeutics, co-founded by MIT's Li-Huei Tsai, is advancing to phase 3 trials of the gamma therapy in Alzheimer's patients this year.

3 Articles

New Atlas Tech Explorist ScienceDaily